Novo Nordisk A/S ADR buy The Goldman Sachs Group, Inc.
Start price
30.05.24
/
50%
€123.00
Target price
30.05.25
€144.02
Performance (%)
-49.11%
End price
31.05.25
€62.60
Summary
This prediction ended on 31.05.25 with a price of €62.60. Massive losses of -49.11% were the result for the BUY prediction by The_Goldman_Sachs_Gr. The_Goldman_Sachs_Gr has a follow-up prediction for Novo Nordisk A/S ADR where he still thinks Novo Nordisk A/S ADR is a Buy. Dividends of €1.56 are taken into consideration when calculating the performance. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Novo Nordisk A/S ADR | 0.908% | 0.908% | -16.276% |
| iShares Core DAX® | -1,28 % | 4,21 % | 7,08 % |
| iShares Nasdaq 100 | -3,34 % | -1,74 % | 26,18 % |
| iShares Nikkei 225® | -4,29 % | -1,62 % | 44,32 % |
| iShares S&P 500 | -2,31 % | -0,10 % | 20,82 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Novo Nordisk A/S ADR diskutieren
Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $156.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
In the thread Trading Novo Nordisk A/S ADR
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Current prediction by The_Goldman_Sachs_Gr for Novo Nordisk A/S ADR
Novo Nordisk A/S ADR
Start price
Target price
Perf. (%)
€42.70
28.11.25
28.11.25
€46.61
28.11.26
28.11.26
-6.28%
21.08.26
21.08.26
